Biogen: The Drive to Discover...The Drive to Deliver Home
SitemapContact Us
Research & Development

Research & Development

Biogen Research

Partnerships & Strategic Alliances

Product Pipeline


Home

Product Pipeline

Research Preclinical Phase I Phase II Phase III Regulatory Filing Approved Phase IV
AVONEX® (Interferon beta-1a)
MS-Open Label
MS-Monosymptomatic (CHAMPS)
MS-Secondary Progressive
MS-Combination Trials
AMEVIVE® (alefacept)
Psoriasis
ANTEGREN® (natalizumab)
MS
Crohn's disease
ADENTRI™ (adenosine A1 antagonist)
Congestive heart failure
Lymphotoxin Beta Receptor
Autoimmune diseases
Interferon Beta Gene Delivery
Cancer indications
VLA-1 mAb
Inflammation and Fibrosis
VLA-4 Inhibitor
Inflammation
LTBR mAb
Solid tumors

MS - Monosymptomatic (CHAMPS)

AVONEX is the first treatment approved for MS patients who have their first clinical MS attack and have a brain MRI scan that suggests MS. This use was approved in Europe in 2002 and by the FDA in 2003.


About BIOGEN
BIOGEN in the Community
Products & Pipeline
Investor Relations
News & Media
Career Opportunities